Bank of Montreal Can Increases Stock Holdings in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS)

Bank of Montreal Can boosted its holdings in shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS - Free Report) by 105.8% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 80,991 shares of the company's stock after purchasing an additional 41,635 shares during the period. Bank of Montreal Can owned about 0.07% of Apellis Pharmaceuticals worth $2,584,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Vanguard Group Inc. increased its holdings in shares of Apellis Pharmaceuticals by 2.3% during the 4th quarter. Vanguard Group Inc. now owns 10,046,025 shares of the company's stock valued at $320,569,000 after purchasing an additional 230,450 shares in the last quarter. JPMorgan Chase & Co. increased its holdings in Apellis Pharmaceuticals by 23.3% in the third quarter. JPMorgan Chase & Co. now owns 3,884,730 shares of the company's stock valued at $112,036,000 after buying an additional 735,160 shares in the last quarter. Jennison Associates LLC raised its position in shares of Apellis Pharmaceuticals by 51.6% in the fourth quarter. Jennison Associates LLC now owns 2,760,404 shares of the company's stock worth $88,084,000 after acquiring an additional 939,289 shares during the period. Geode Capital Management LLC raised its position in shares of Apellis Pharmaceuticals by 1.6% in the fourth quarter. Geode Capital Management LLC now owns 1,838,952 shares of the company's stock worth $58,699,000 after acquiring an additional 28,426 shares during the period. Finally, National Bank of Canada FI boosted its stake in shares of Apellis Pharmaceuticals by 266,361.5% during the 4th quarter. National Bank of Canada FI now owns 1,385,600 shares of the company's stock worth $44,214,000 after acquiring an additional 1,385,080 shares in the last quarter. 96.29% of the stock is currently owned by institutional investors and hedge funds.

Apellis Pharmaceuticals Stock Down 3.7 %

Shares of APLS stock traded down $0.66 during trading on Tuesday, reaching $17.37. The company's stock had a trading volume of 2,766,709 shares, compared to its average volume of 2,154,211. Apellis Pharmaceuticals, Inc. has a 1-year low of $17.02 and a 1-year high of $50.98. The stock's 50-day moving average price is $23.31 and its 200 day moving average price is $27.86. The company has a market capitalization of $2.18 billion, a price-to-earnings ratio of -8.56 and a beta of 0.85. The company has a debt-to-equity ratio of 1.91, a current ratio of 4.36 and a quick ratio of 3.73.

Apellis Pharmaceuticals (NASDAQ:APLS - Get Free Report) last posted its quarterly earnings results on Friday, February 28th. The company reported ($0.29) EPS for the quarter, topping the consensus estimate of ($0.37) by $0.08. The business had revenue of $212.50 million during the quarter, compared to the consensus estimate of $197.92 million. Apellis Pharmaceuticals had a negative net margin of 34.97% and a negative return on equity of 103.11%. The company's quarterly revenue was up 45.2% compared to the same quarter last year. During the same quarter in the previous year, the firm posted ($0.73) earnings per share. On average, research analysts anticipate that Apellis Pharmaceuticals, Inc. will post -1.7 EPS for the current year.

Analyst Ratings Changes

Several equities analysts recently weighed in on APLS shares. Royal Bank of Canada cut their price target on Apellis Pharmaceuticals from $24.00 to $21.00 and set a "sector perform" rating for the company in a research note on Monday. Wedbush reduced their target price on Apellis Pharmaceuticals from $30.00 to $29.00 and set a "neutral" rating for the company in a research note on Monday, March 3rd. HC Wainwright reissued a "buy" rating and issued a $57.00 price target on shares of Apellis Pharmaceuticals in a report on Monday, March 3rd. Scotiabank increased their price objective on shares of Apellis Pharmaceuticals from $30.00 to $31.00 and gave the company a "sector perform" rating in a report on Wednesday, April 2nd. Finally, The Goldman Sachs Group cut their target price on shares of Apellis Pharmaceuticals from $36.00 to $32.00 and set a "neutral" rating for the company in a research note on Monday, March 3rd. Eight analysts have rated the stock with a hold rating, ten have assigned a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average price target of $45.35.

Insiders Place Their Bets

In related news, CEO Cedric Francois sold 13,551 shares of the company's stock in a transaction that occurred on Wednesday, January 22nd. The shares were sold at an average price of $30.43, for a total transaction of $412,356.93. Following the sale, the chief executive officer now directly owns 418,519 shares in the company, valued at approximately $12,735,533.17. This represents a 3.14 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CAO James George Chopas sold 1,096 shares of the firm's stock in a transaction that occurred on Wednesday, January 22nd. The shares were sold at an average price of $30.43, for a total transaction of $33,351.28. Following the completion of the sale, the chief accounting officer now directly owns 48,138 shares in the company, valued at approximately $1,464,839.34. This trade represents a 2.23 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 36,011 shares of company stock worth $1,059,969 in the last quarter. 6.80% of the stock is owned by company insiders.

Apellis Pharmaceuticals Company Profile

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).